Therapeutics Solutions International Inc. (OTCMKTS:TSOI) soared 78% after announcing that the FDA has given it cleared to commence phase 3 pivotal study for registration of its JadiCell universal donor stem cell as a COVID-19 related lung failure treatment. In past studies, the company has shown JadiCell’s superiority to other stem cells types, including adipose, bone marrow, placenta, and cord blood.
Equally, JadiCell has demonstrated to be 100% efficient in saving COVID-19 patients’ lives under 85 years. The survival rate in patients above 85 years is 91%. TherapeuticSolutions Director Thomas E Ichim stated that they are delighted to receive the FDA clearance. It means the company is in the last development stage of JadiCell before the commercial launch.
Recently, the company announced that Campbell Neurosciences, its Spin-Off Company, had presented a video describing its current position and future path regarding suicide diagnosis and prevention. In addition, the company has created the clinically-approved suicidal ideations diagnostic test, the Campbell Score, with a variety of intervention methodologies employing immune modulation and regenerative approaches. So, TSOI is worth watching.
On Thursday, TSOI stock soared 77.50% at $0.0687 with more than 174.25 million shares, compared to its average volume of 7.59 million shares. The stock has moved within a range of $0.0394 – 0.0832 after opening the trade at $0.0395.